Clinical Trial

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Study acronym: IT-PD1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-10-27; most recent amendment 2025-03-31.
Trial Details
NCT Number NCT05112549
Lead Sponsor University Hospital Tuebingen
Conditions Leptomeningeal Disease
Enrollment 46 participants
Start Date 2021-10-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-03